BioXcel Therapeutics (FRA:BX2) Accounts Payable : €15.84 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Accounts Payable?

BioXcel Therapeutics's Accounts Payable for the quarter that ended in Mar. 2024 was €15.84 Mil.

BioXcel Therapeutics's quarterly Accounts Payable increased from Sep. 2023 (€10.00 Mil) to Dec. 2023 (€12.52 Mil) and increased from Dec. 2023 (€12.52 Mil) to Mar. 2024 (€15.84 Mil).

BioXcel Therapeutics's annual Accounts Payable increased from Dec. 2021 (€4.14 Mil) to Dec. 2022 (€9.66 Mil) and increased from Dec. 2022 (€9.66 Mil) to Dec. 2023 (€12.52 Mil).

BioXcel Therapeutics Accounts Payable Historical Data

The historical data trend for BioXcel Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Accounts Payable Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

4.46

3.27

4.14

9.66

12.52

BioXcel Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															7.23	10.34	10.00	12.52	15.84

BioXcel Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

BioXcel Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (FRA:BX2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (FRA:BX2) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

BTAI:USA BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

BioXcel Therapeutics (FRA:BX2) Headlines

No Headlines